Meta Pixel

News and Announcements

Actinogen Medical CEO Interview

  • Published September 23, 2016 11:18AM UTC
  • Publisher Wholesale Investor
  • Categories Executive Interviews

Actinogen Medical Ltd (ASX: ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.

Actinogen is developing Xanamem™ as a novel treatment approach to Alzheimer’s disease and other age-related neurodegenerative diseases. Xanamem™ displays high potency and selectivity for inhibiting the activity of a key enzyme in the brain, which converts cortisone to cortisol. Cortisol is also known as the stress hormone, and elevated levels of cortisol has previously been linked to cognitive impairment. The pivotal human proof of concept study, also known as XanADu, commenced in 2Q2016.

Please listen to Dr. Bill Ketelbey, Founder and CEO & Managing Director of Actinogen Medical below.

Capital Insights
The Great Convergence: The $16 Trillion Shift Defining the Next Era of Wealth

A quiet but powerful trend is re-architecting global finance: the great convergence of traditional finance and digital assets. With Boston Consulting Group forecasting the tokenized real-world assets market to hit $16 trillion by 2030, this isn’t speculation—it’s a new institutional reality. Discover the infrastructure being built, the power of tokenization, and how mature DeFi strategies are defining the next era of wealth.

Capital Insights
Navigating the Future of Capital: Insights from MENA’s VC and PE Leaders

The venture capital and private equity landscape in the MENA (Middle East and North Africa) region is experiencing dynamic shifts, driven by rapid technological advancements, evolving investor demands, and unique regional priorities. A recent panel featuring prominent figures in the MENA investment scene offered a glimpse into these transformations, highlighting key trends for founders and […]

Join over 45,000+ sophisticated investors

Join Now